Wissel Holding GmbH is the owner of the HWI group of companies. It sold its company HWI regulatory services GmbH to TentaConsult Pharma & Med GmbH on 1 August 2022.
The HWI group has been successfully offering its services to the pharmaceutical and biotech industry in the areas of laboratory services, vigilance, quality and drug development for over 30 years. In its strategic orientation, the HWI group will increasingly focus on the development and testing of innovative drugs with chemical and biotechnological active ingredients for parenteral, nasal and oral applications as well as the digitalisation of pharmacovigilance.
"Our purpose is to discover new ways to improve people's lives. With novel technologies and innovative services, we aim to advance the development of highly effective medicines for everyone" says Dr Stefan Wissel, owner of the HWI group of companies.
With HWI regulatory services GmbH, formerly i.DRAS GmbH, TentaConsult takes over a powerful regulatory services provider that perfectly complements TentaConsult's portfolio and customer base. With significantly strengthened capacities, TentaConsult will be even better able to live up to its claim of being a globally active full-service provider within the Tentamus Group.
"We started out in 2020 with TentaConsult to develop into a market-leading consulting company, especially for medicinal products and medical devices. We have now achieved this goal with the acquisition of HWI regulatory services GmbH. We are looking forward to a successful future together. In doing so, we are clearly focussing on the needs of our clients, the steady growth and the consistent expansion of our range of services!" says Ralf Sibbing, Managing Partner of TentaConsult.
With this transfer, both companies strengthen their core competences in order to be able to serve their clients even better as specialists.
For further information, please visit www.hwi-group.de
For further information, please visit www.tentaconsult.com
The HWI group has been successfully offering its services to the pharmaceutical and biotech industry in the areas of laboratory services, vigilance, quality and drug development for over 30 years. In its strategic orientation, the HWI group will increasingly focus on the development and testing of innovative drugs with chemical and biotechnological active ingredients for parenteral, nasal and oral applications as well as the digitalisation of pharmacovigilance.
"Our purpose is to discover new ways to improve people's lives. With novel technologies and innovative services, we aim to advance the development of highly effective medicines for everyone" says Dr Stefan Wissel, owner of the HWI group of companies.
With HWI regulatory services GmbH, formerly i.DRAS GmbH, TentaConsult takes over a powerful regulatory services provider that perfectly complements TentaConsult's portfolio and customer base. With significantly strengthened capacities, TentaConsult will be even better able to live up to its claim of being a globally active full-service provider within the Tentamus Group.
"We started out in 2020 with TentaConsult to develop into a market-leading consulting company, especially for medicinal products and medical devices. We have now achieved this goal with the acquisition of HWI regulatory services GmbH. We are looking forward to a successful future together. In doing so, we are clearly focussing on the needs of our clients, the steady growth and the consistent expansion of our range of services!" says Ralf Sibbing, Managing Partner of TentaConsult.
With this transfer, both companies strengthen their core competences in order to be able to serve their clients even better as specialists.
For further information, please visit www.hwi-group.de
For further information, please visit www.tentaconsult.com
